| New Additions to the Interferon Portfolio! | |
|
Recombinant Human IFN-beta and Mouse IFN-beta: New proteins, now developed and manufactured by R&D Systems. |
|
|
Recombinant Mouse IFN-kappa: Mouse IFN-kappa is exclusive to R&D Systems. |
|
|
B19R and B8R IFN Inhibitors: The viral protein B19R blocks all Type I interferons and B8R blocks IFN-gamma. |
|
|
See All IFN-related Protein Products |
|
|
IFN-alpha proteins |
IFN-beta proteins |
Since being discovered in the late 1950s by Isaacs and Lindemann, Interferons, as they were termed, have been the focus of extensive study with approximately 160,000 journal articles published over the past 50 years. Interferons are often referred to as the first line of host defense against viral infection.
Once triggered, they initiate a signaling cascade through the JAK/STAT pathway resulting in the regulation of numerous gene products. Based on specific function, structure, and receptor binding, interferons have been divided into 3 distinct families: Type I, type II, and type III. The type I family is the largest and includes 13 IFN-alpha subtypes, IFN-beta, IFN-epsilon, IFN-kappa, IFN-omega, and others. The type II family consists of a single member, IFN-gamma, and the type III family includes IL-29/IFN-lambda 1, IL-28A/IFN-lambda 2, IL-28B/IFN-lambda 3, and IFN-lambda 4. Based on their immunomodulatory effects, interferons have been developed to treat several diseases, including multiple sclerosis, hairy cell leukemia, and chronic hepatitis.In addition, recent research has increased focus on the IFN-lambda proteins as potential anti-cancer treatments.
| New Data! | |
 Recombinant Human IFN-β demonstrates antiviral activity in HeLa cells infected with EMC virus. The ED50 for the antiviral effect is approximately 20 pg/mL. The specific activity of IFN-beta is approximately 2.8 x 105 IU/µg, which is calibrated against the human IFN-beta WHO International Standard (NIBSC code: 00/572). |
 Recombinant Mouse IFN-β demonstrates antiviral activity in L-929 mouse fibroblast cells infected with EMC virus. The ED50 for the antiviral effect is approximately 1-6 pg/mL. |
 Recombinant Mouse IFN-κ demonstrates antiviral activity in L-929 mouse fibroblast cells infected with EMC virus. The ED50 for this effect is typically 0.2-1.2 ng/mL. |
 Recombinant Viral B8R inhibits Type 2 IFN activity. Recombinant human IFN-γ protects HeLa cells from viral-mediated lysis (yellow). Recombinant viral B8R inhibits the protective effect of 10 ng/mL IFN-γ (blue). The ED50 for this effect is typically 0.5-3 ng/mL. |
 Recombinant Viral B19R inhibits Type I IFN Activity. Recombinant human IFN-α2 protects HeLa cells from viral-mediated lysis (yellow). Recombinant viral B19R inhibits the protective effect of 1 ng/mL IFN-α2 (blue). The ED50 for this effect is typically 0.3-1.8 ng/mL. |
|